Regulatory PathRegulatory requirements compared

Active substance

Estazolam

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
ESTAZOLAM1MG; 2MGtablet · oralNOVITIUM PHARMAPrescription3 Jul 1997
ESTAZOLAM1MG; 2MGtablet · oralDR REDDYS LABS SAPrescription10 Jul 1997
ESTAZOLAM1MG; 2MGtablet · oralWATSON LABSPrescription19 Aug 1997
PROSOM1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**tablet · oralABBOTTDiscontinued26 Dec 1990

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACESTAZOLAM 1 MG TABLET$0.88416per EA23 Sep 2026
US NADACESTAZOLAM 2 MG TABLET$0.83942per EA23 Sep 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

All safety entries for estazolam →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.